Winslow Capital Management LLC trimmed its stake in Zoetis Inc (NYSE:ZTS) by 3.7% during the second quarter, Holdings Channel reports. The institutional investor owned 2,890,556 shares of the company’s stock after selling 110,021 shares during the period. Winslow Capital Management LLC’s holdings in Zoetis were worth $246,247,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Polen Capital Management LLC grew its position in shares of Zoetis by 125.3% in the 1st quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company’s stock valued at $746,883,000 after buying an additional 4,974,081 shares during the last quarter. BlackRock Inc. grew its position in shares of Zoetis by 6.7% in the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock valued at $3,429,736,000 after buying an additional 2,584,199 shares during the last quarter. Amundi Pioneer Asset Management Inc. grew its position in shares of Zoetis by 319.9% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock valued at $231,187,000 after buying an additional 2,109,036 shares during the last quarter. Banque Pictet & Cie SA grew its position in shares of Zoetis by 5,516.1% in the 2nd quarter. Banque Pictet & Cie SA now owns 1,679,617 shares of the company’s stock valued at $143,087,000 after buying an additional 1,649,710 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Zoetis by 22.3% in the 2nd quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock valued at $460,890,000 after buying an additional 985,586 shares during the last quarter. 89.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:ZTS opened at $89.58 on Monday. Zoetis Inc has a 1-year low of $62.79 and a 1-year high of $93.67. The firm has a market cap of $43.09 billion, a P/E ratio of 37.33, a price-to-earnings-growth ratio of 1.84 and a beta of 1.02. The company has a quick ratio of 2.92, a current ratio of 4.38 and a debt-to-equity ratio of 2.50.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. During the same quarter last year, the business earned $0.53 EPS. The business’s revenue was up 11.5% on a year-over-year basis. research analysts expect that Zoetis Inc will post 3.07 earnings per share for the current fiscal year.

In other news, CFO Glenn David sold 16,385 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $92.20, for a total value of $1,510,697.00. Following the completion of the sale, the chief financial officer now owns 29,234 shares in the company, valued at approximately $2,695,374.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Roxanne Lagano sold 2,000 shares of the firm’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $84.76, for a total transaction of $169,520.00. Following the completion of the sale, the insider now owns 22,023 shares of the company’s stock, valued at approximately $1,866,669.48. The disclosure for this sale can be found here. Insiders sold a total of 213,467 shares of company stock valued at $19,488,185 in the last 90 days. Company insiders own 0.35% of the company’s stock.

A number of brokerages recently weighed in on ZTS. Cantor Fitzgerald set a $98.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Stifel Nicolaus increased their price target on shares of Zoetis from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Morgan Stanley increased their price target on shares of Zoetis from $87.00 to $92.00 and gave the stock a “hold” rating in a research note on Friday, August 3rd. Jefferies Financial Group set a $96.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, July 13th. Finally, Bank of America increased their price target on shares of Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $90.53.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What is a Fiduciary?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.